The prevalence of gene mutations in homologous recombination repair pathways in Japanese patients with metastatic castration‐resistant prostate cancer in real‐world clinical practice: The multi‐institutional observational ZENSHIN study

The prevalence of gene mutations in homologous recombination repair pathways in Japanese patients with metastatic castration‐resistant prostate cancer in real‐world clinical practice: The multi‐institutional observational ZENSHIN study

Abstract Background Metastatic castration‐resistant prostate cancer (mCRPC) is a genetically heterogeneous disease with a poor prognosis. The prevalence of mutations in homologous recombination repair (HRR) pathway genes, including BRCA1/2, as well as treatment patterns and clinical outcomes, are no...

Full description

Bibliographic Details
Main Authors: Hiroji Uemura, Mototsugu Oya, Toshiyuki Kamoto, Mikio Sugimoto, Kenta Shinozaki, Kiyomi Morita, Ryo Koto, Mai Takahashi, Masahiro Nii, Eisei Shin, Norio Nonomura
Format: Article
Language:English
Published: Wiley 2023-03-01
Series:Cancer Medicine
Subjects:
BRCA
homologous recombination repair
metastatic castration‐resistance prostate cancer
survival
Online Access:https://doi.org/10.1002/cam4.5333

Internet

https://doi.org/10.1002/cam4.5333

Similar Items